{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T22:32:57Z","timestamp":1788474777471,"version":"build-2803163510"},"reference-count":132,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Paediatric Respiratory Reviews"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.prrv.2023.09.001","type":"journal-article","created":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T04:34:45Z","timestamp":1694752485000},"page":"10-19","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Trials and tribulations of highly effective modulator therapies in cystic fibrosis"],"prefix":"10.1016","volume":"48","author":[{"given":"Nathan","family":"Lieu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernadette J.","family":"Prentice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Penelope","family":"Field","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominic A.","family":"Fitzgerald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10059","key":"10.1016\/j.prrv.2023.09.001_b0005","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1016\/S0140-6736(16)00576-6","article-title":"Cystic fibrosis","volume":"388","author":"Elborn","year":"2016","journal-title":"Lancet"},{"issue":"9678","key":"10.1016\/j.prrv.2023.09.001_b0010","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1016\/S0140-6736(09)60327-5","article-title":"Cystic fibrosis","volume":"373","author":"O'Sullivan","year":"2009","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.prrv.2023.09.001_b0015","doi-asserted-by":"crossref","first-page":"4404","DOI":"10.1073\/pnas.1215982110","article-title":"Vx-770 potentiates CFTR function by promoting decoupling between the gating cycle and ATP hydrolysis cycle","volume":"110","author":"Jih","year":"2013","journal-title":"PNAS"},{"issue":"2","key":"10.1016\/j.prrv.2023.09.001_b0020","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S2213-2600(15)00545-7","article-title":"Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2\u20135 years with cystic fibrosis and a CFTR gating mutation (KIWI): an open-label, single-arm study","volume":"4","author":"Davies","year":"2016","journal-title":"Lancet Respir Med"},{"issue":"11","key":"10.1016\/j.prrv.2023.09.001_b0025","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1164\/rccm.201301-0153OC","article-title":"Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation","volume":"187","author":"Davies","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"10.1016\/j.prrv.2023.09.001_b0030","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1164\/rccm.202008-3177OC","article-title":"Ivacaftor in infants aged 4 to <12 months with cystic fibrosis and a gating mutation. results of a two-part phase 3 clinical trial","volume":"203","author":"Davies","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"issue":"11","key":"10.1016\/j.prrv.2023.09.001_b0035","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/S2213-2600(14)70218-8","article-title":"Long-term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp-CFTR mutation: a phase 3, open-label extension study (PERSIST)","volume":"2","author":"McKone","year":"2014","journal-title":"Lancet Respir Med"},{"issue":"18","key":"10.1016\/j.prrv.2023.09.001_b0040","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1056\/NEJMoa1105185","article-title":"A CFTR potentiator in patients with cystic fibrosis and the G551D mutation","volume":"365","author":"Ramsey","year":"2011","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.prrv.2023.09.001_b0045","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.jcf.2019.03.009","article-title":"An open-label extension study of ivacaftor in children with CF and a CFTR gating mutation initiating treatment at age 2\u20135 years (KLIMB)","volume":"18","author":"Rosenfeld","year":"2019","journal-title":"J Cyst Fibros"},{"issue":"7","key":"10.1016\/j.prrv.2023.09.001_b0050","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S2213-2600(18)30202-9","article-title":"Ivacaftor treatment of cystic fibrosis in children aged 12 to <24 months and with a CFTR gating mutation (ARRIVAL): a phase 3 single-arm study","volume":"6","author":"Rosenfeld","year":"2018","journal-title":"Lancet Respir Med"},{"issue":"8","key":"10.1016\/j.prrv.2023.09.001_b0055","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/S2213-2600(13)70182-6","article-title":"Assessment of clinical response to ivacaftor with lung clearance index in cystic fibrosis patients with a G551D-CFTR mutation and preserved spirometry: a randomised controlled trial","volume":"1","author":"Davies","year":"2013","journal-title":"Lancet Respir Med"},{"issue":"5","key":"10.1016\/j.prrv.2023.09.001_b0060","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1136\/thoraxjnl-2015-207894","article-title":"Lung clearance index response in patients with CF with class III CFTR mutations","volume":"71","author":"Kane","year":"2016","journal-title":"Thorax"},{"key":"10.1016\/j.prrv.2023.09.001_b0065","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.2147\/DDDT.S153719","article-title":"Lumacaftor-ivacaftor in the treatment of cystic fibrosis: design, development and place in therapy","volume":"13","author":"Connett","year":"2019","journal-title":"Drug Des Devel Ther"},{"issue":"3","key":"10.1016\/j.prrv.2023.09.001_b0070","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1056\/NEJMoa1409547","article-title":"Lumacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR","volume":"373","author":"Wainwright","year":"2015","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.prrv.2023.09.001_b0075","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1513\/AnnalsATS.201609-689OC","article-title":"Lumacaftor\/ivacaftor treatment of patients with cystic fibrosis heterozygous for F508del-CFTR","volume":"14","author":"Rowe","year":"2017","journal-title":"Ann Am Thorac Soc"},{"issue":"4","key":"10.1016\/j.prrv.2023.09.001_b0080","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/S2213-2600(18)30460-0","article-title":"Safety, pharmacokinetics, and pharmacodynamics of lumacaftor and ivacaftor combination therapy in children aged 2\u20135 years with cystic fibrosis homozygous for F508del-CFTR: an open-label phase 3 study","volume":"7","author":"McNamara","year":"2019","journal-title":"Lancet Respir Med"},{"issue":"10","key":"10.1016\/j.prrv.2023.09.001_b0085","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1164\/rccm.202204-0734OC","article-title":"A phase 3, open-label study of lumacaftor\/ivacaftor in children 1 to less than 2 years of age with cystic fibrosis homozygous for F508del-CFTR","volume":"206","author":"Rayment","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"issue":"7","key":"10.1016\/j.prrv.2023.09.001_b0090","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/S2213-2600(17)30215-1","article-title":"Efficacy and safety of lumacaftor and ivacaftor in patients aged 6\u201311 years with cystic fibrosis homozygous for F508del-CFTR: a randomised, placebo-controlled phase 3 trial","volume":"5","author":"Ratjen","year":"2017","journal-title":"Lancet Respir Med"},{"issue":"3","key":"10.1016\/j.prrv.2023.09.001_b0095","first-page":"174","article-title":"Safety and effectiveness of lumacaftor-ivacaftor in adults with cystic fibrosis: A single-center Canadian experience","volume":"4","author":"Sergeev","year":"2020","journal-title":"Can J Respir, Crit Care, Sleep Med"},{"issue":"1","key":"10.1016\/j.prrv.2023.09.001_b0100","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3390\/jcm10010023","article-title":"Real-world safety of CFTR modulators in the treatment of cystic fibrosis: A systematic review","volume":"10","author":"Dagenais","year":"2021","journal-title":"J Clin Med"},{"issue":"4","key":"10.1016\/j.prrv.2023.09.001_b0105","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.jcf.2020.02.018","article-title":"Outcomes of pregnancy in women with cystic fibrosis (CF) taking CFTR modulators \u2013 an international survey","volume":"19","author":"Nash","year":"2020","journal-title":"J Cyst Fibros"},{"issue":"3","key":"10.1016\/j.prrv.2023.09.001_b0110","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.jcf.2017.02.009","article-title":"Immediate effects of lumacaftor\/ivacaftor administration on lung function in patients with severe cystic fibrosis lung disease","volume":"16","author":"Popowicz","year":"2017","journal-title":"J Cyst Fibros"},{"issue":"70","key":"10.1016\/j.prrv.2023.09.001_b0115","first-page":"1","article-title":"Evidence of small airways disease and the immediate effects of lumacaftor\/ivacaftor in children with cystic fibrosis","volume":"113","author":"Finnegan","year":"2020","journal-title":"Ir Med J"},{"issue":"2","key":"10.1016\/j.prrv.2023.09.001_b0120","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1164\/rccm.201906-1227OC","article-title":"Real-life safety and effectiveness of lumacaftor-ivacaftor in patients with cystic fibrosis","volume":"201","author":"Burgel","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"issue":"8","key":"10.1016\/j.prrv.2023.09.001_b0125","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.3390\/pharmaceutics14081674","article-title":"Therapeutic drug monitoring of ivacaftor, lumacaftor, tezacaftor, and elexacaftor in cystic fibrosis: where are we now?","volume":"14","author":"Choong","year":"2022","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.prrv.2023.09.001_b0130","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jcf.2020.07.023","volume":"20","author":"Davies","year":"2021","journal-title":"J Cyst Fibros"},{"issue":"21","key":"10.1016\/j.prrv.2023.09.001_b0135","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1056\/NEJMoa1709847","article-title":"Tezacaftor-ivacaftor in residual-function heterozygotes with cystic fibrosis","volume":"377","author":"Rowe","year":"2017","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.prrv.2023.09.001_b0140","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1056\/NEJMoa1709846","article-title":"Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del","volume":"377","author":"Taylor-Cousar","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.prrv.2023.09.001_b0145","unstructured":"(TGA), T.G.A. Trikaftor. 2021 [cited 2023 May]; Available from: https:\/\/www.tga.gov.au\/resources\/auspmd\/trikafta."},{"issue":"10212","key":"10.1016\/j.prrv.2023.09.001_b0150","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.prrv.2023.09.001_b0155","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S2213-2600(21)00454-9","article-title":"Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial","volume":"10","author":"Sutharsan","year":"2022","journal-title":"Lancet Respir Med"},{"issue":"5","key":"10.1016\/j.prrv.2023.09.001_b0160","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1164\/rccm.202108-1986OC","article-title":"Clinical effectiveness of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis: a clinical trial","volume":"205","author":"Nichols","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"issue":"11","key":"10.1016\/j.prrv.2023.09.001_b0165","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1164\/rccm.202202-0392OC","article-title":"Efficacy and safety of elexacaftor\/tezacaftor\/ivacaftor in children 6 through 11 years of age with cystic fibrosis heterozygous for f508del and a minimal function mutation: a phase 3B, randomized, placebo-controlled study","volume":"206","author":"Mall","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"issue":"12","key":"10.1016\/j.prrv.2023.09.001_b0170","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1164\/rccm.202102-0509OC","article-title":"A phase 3 open-label study of elexacaftor\/tezacaftor\/ivacaftor in children 6 through 11 years of age with cystic fibrosis and at least one F508del allele","volume":"203","author":"Zemanick","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.prrv.2023.09.001_b0175","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1164\/rccm.202301-0084OC","article-title":"Phase 3 open-label clinical trial of elexacaftor\/tezacaftor\/ivacaftor in children aged 2\u20135 years with cystic fibrosis and at least one F508del allele","volume":"208","author":"Goralski","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"issue":"19","key":"10.1016\/j.prrv.2023.09.001_b0180","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor\u2013tezacaftor\u2013ivacaftor for cystic fibrosis with a single Phe508del allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.prrv.2023.09.001_b0185","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1056\/NEJMoa1807119","article-title":"VX-659\u2013tezacaftor\u2013ivacaftor in patients with cystic fibrosis and one or two Phe508del alleles","volume":"379","author":"Davies","year":"2018","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.prrv.2023.09.001_b0190","doi-asserted-by":"crossref","first-page":"411","DOI":"10.4254\/wjh.v14.i2.411","article-title":"Cystic fibrosis patients on cystic fibrosis transmembrane conductance regulator modulators have a reduced incidence of cirrhosis","volume":"14","author":"Ramsey","year":"2022","journal-title":"World J Hepatol"},{"issue":"2","key":"10.1016\/j.prrv.2023.09.001_b0195","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1164\/rccm.201404-0703OC","article-title":"Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosis","volume":"190","author":"Rowe","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.prrv.2023.09.001_b0200","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jcf.2015.01.008","article-title":"Effect of ivacaftor in patients with advanced cystic fibrosis and a G551D-CFTR mutation: Safety and efficacy in an expanded access program in the United States","volume":"15","author":"Taylor-Cousar","year":"2016","journal-title":"J Cyst Fibros"},{"issue":"9","key":"10.1016\/j.prrv.2023.09.001_b0205","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9092706","article-title":"Impact on fertility, pregnancy, and lactation in women with cystic fibrosis","volume":"9","author":"Taylor-Cousar","year":"2020","journal-title":"J Clin Med"},{"issue":"11","key":"10.1016\/j.prrv.2023.09.001_b0210","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1513\/AnnalsATS.201902-122OC","article-title":"Ivacaftor is associated with reduced lung infection by key cystic fibrosis pathogens. A cohort study using national registry data","volume":"16","author":"Frost","year":"2019","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.prrv.2023.09.001_b0215","article-title":"Eradication of nontuberculous mycobacteria in people with cystic fibrosis treated with elexacaftor\/tezacaftor\/ivacaftor: a multicenter cohort study","author":"Wiesel","year":"2023","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.prrv.2023.09.001_b0220","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.jpeds.2018.05.018","article-title":"Energy balance and mechanisms of weight gain with ivacaftor treatment of cystic fibrosis gating mutations","volume":"201","author":"Stallings","year":"2018","journal-title":"J Pediatr"},{"key":"10.1016\/j.prrv.2023.09.001_b0225","unstructured":"Leonard, A., et al., Nutritional considerations for a new era: A CF foundation position paper. J Cystic Fibrosis."},{"issue":"7","key":"10.1016\/j.prrv.2023.09.001_b0230","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1016\/j.jand.2020.03.014","article-title":"Effect of CFTR modulators on anthropometric parameters in individuals with cystic fibrosis: an evidence analysis center systematic review","volume":"121","author":"Bailey","year":"2021","journal-title":"J Acad Nutr Diet"},{"key":"10.1016\/j.prrv.2023.09.001_b0235","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcf.2023.06.010","article-title":"Body mass index and nutritional intake following Elexacaftor\/Tezacaftor\/Ivacaftor modulator therapy in adults with cystic fibrosis","author":"Caley","year":"2023","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.prrv.2023.09.001_b0240","doi-asserted-by":"crossref","DOI":"10.1016\/j.nut.2020.111124","volume":"85","author":"King","year":"2021","journal-title":"Nutrition"},{"issue":"2","key":"10.1016\/j.prrv.2023.09.001_b0245","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jcf.2021.11.012","article-title":"Effect of elexacaftor-tezacaftor-ivacaftor on body weight and metabolic parameters in adults with cystic fibrosis","volume":"21","author":"Petersen","year":"2022","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.prrv.2023.09.001_b0250","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcf.2023.07.001","article-title":"Improvement of lipid and lipoprotein profiles in children and adolescents with cystic fibrosis on CFTR modulator therapy","author":"Yuzyuk","year":"2023","journal-title":"J Cyst Fibros"},{"issue":"34_suppl","key":"10.1016\/j.prrv.2023.09.001_b0255","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1177\/014107689809134S07","article-title":"Pathology of pancreatic and intestinal disorders in cystic fibrosis","volume":"91","author":"Wilschanski","year":"1998","journal-title":"J R Soc Med"},{"issue":"2","key":"10.1016\/j.prrv.2023.09.001_b0260","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/path.4634","article-title":"Pancreatic pathophysiology in cystic fibrosis","volume":"238","author":"Gibson-Corley","year":"2016","journal-title":"J Pathol"},{"issue":"2","key":"10.1016\/j.prrv.2023.09.001_b0265","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1513\/AnnalsATS.201909-671CME","article-title":"The extrapulmonary effects of cystic fibrosis transmembrane conductance regulator modulators in cystic fibrosis","volume":"17","author":"Sergeev","year":"2020","journal-title":"Ann Am Thorac Soc"},{"issue":"4","key":"10.1016\/j.prrv.2023.09.001_b0270","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.jcf.2023.02.013","article-title":"Acute pancreatitis in pancreatic-insufficient cystic fibrosis patients treated with CFTR modulators","volume":"22","author":"Sadras","year":"2023","journal-title":"J Cyst Fibros"},{"issue":"4","key":"10.1016\/j.prrv.2023.09.001_b0275","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.jcf.2021.09.010","article-title":"CFTR modulators increase risk of acute pancreatitis in pancreatic insufficient patients with cystic fibrosis","volume":"21","author":"Gould","year":"2022","journal-title":"J Cyst Fibros"},{"issue":"8","key":"10.1016\/j.prrv.2023.09.001_b0280","doi-asserted-by":"crossref","DOI":"10.1002\/ppul.24353","article-title":"Time for a gut check: pancreatic sufficiency resulting from CFTR modulator use","volume":"54","author":"Megalaa","year":"2019","journal-title":"Pediatr Pulmonol"},{"issue":"1","key":"10.1016\/j.prrv.2023.09.001_b0285","first-page":"6","article-title":"Pancreatitis in a patient with cystic fibrosis taking ivacaftor","volume":"7","author":"Petrocheilou","year":"2020","journal-title":"Children (Basel)"},{"key":"10.1016\/j.prrv.2023.09.001_b0290","doi-asserted-by":"crossref","unstructured":"Francalanci, M., et al., Nutritional status and circulating levels of fat-soluble vitamins in cystic fibrosis patients: a cohort study and evaluation of the Effect of CFTR Modulators. Children (Basel), 2023. 10(2).","DOI":"10.3390\/children10020252"},{"issue":"3","key":"10.1016\/j.prrv.2023.09.001_b0295","doi-asserted-by":"crossref","first-page":"483","DOI":"10.3390\/antiox10030483","article-title":"CFTR modulator therapy with lumacaftor\/ivacaftor alters plasma concentrations of lipid-soluble vitamins A and E in patients with cystic fibrosis","volume":"10","author":"Sommerburg","year":"2021","journal-title":"Antioxidants (Basel)"},{"issue":"1","key":"10.1016\/j.prrv.2023.09.001_b0300","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jcf.2020.06.015","article-title":"Lumacaftor\/ivacaftor improves liver cholesterol metabolism but does not influence hypocholesterolemia in patients with cystic fibrosis","volume":"20","author":"Gelzo","year":"2021","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.prrv.2023.09.001_b0305","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcf.2023.08.002","article-title":"The impact of elexacaftor\/tezacaftor\/ivacaftor on fat-soluble vitamin levels in people with cystic fibrosis","author":"Hergenroeder","year":"2023","journal-title":"J Cyst Fibros"},{"issue":"3","key":"10.1016\/j.prrv.2023.09.001_b0310","doi-asserted-by":"crossref","first-page":"e217","DOI":"10.1016\/j.jcf.2022.01.010","article-title":"Hypervitaminosis A with fulminant secondary intracranial hypertension following personalized medicine-based Elexacaftor\/Tezacaftor\/Ivacaftor initiation in a preadolescent with cystic fibrosis","volume":"21","author":"Wisniewski","year":"2022","journal-title":"J Cyst Fibros"},{"issue":"1","key":"10.1016\/j.prrv.2023.09.001_b0315","doi-asserted-by":"crossref","first-page":"e6","DOI":"10.1016\/j.jcjo.2021.04.018","article-title":"Papilledema and hypervitaminosis A after elexacaftor\/tezacaftor\/ivacaftor for cystic fibrosis","volume":"57","author":"Miller","year":"2022","journal-title":"Can J Ophthalmol"},{"key":"10.1016\/j.prrv.2023.09.001_b0320","doi-asserted-by":"crossref","unstructured":"Christian, F., et al., Sustained glycemic control with ivacaftor in cystic fibrosis\u2013related diabetes. J Invest Med High Impact Case Rep, 2019. 7: p. 2324709619842898.","DOI":"10.1177\/2324709619842898"},{"issue":"6","key":"10.1016\/j.prrv.2023.09.001_b0325","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/pedi.12026","article-title":"Insulin secretion improves in cystic fibrosis following ivacaftor correction of CFTR: a small pilot study","volume":"14","author":"Bellin","year":"2013","journal-title":"Pediatr Diabetes"},{"issue":"5","key":"10.1016\/j.prrv.2023.09.001_b0330","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1164\/rccm.201405-0882LE","article-title":"Resolution of cystic fibrosis-related diabetes with ivacaftor therapy","volume":"190","author":"Hayes","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"10.1016\/j.prrv.2023.09.001_b0335","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1164\/rccm.201806-1018OC","article-title":"Islet hormone and incretin secretion in cystic fibrosis after four months of ivacaftor therapy","volume":"199","author":"Kelly","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.prrv.2023.09.001_b0340","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.jcf.2018.07.010","article-title":"Continuous glucose monitoring in youth with cystic fibrosis treated with lumacaftor-ivacaftor","volume":"18","author":"Li","year":"2019","journal-title":"J Cyst Fibros"},{"issue":"2","key":"10.1016\/j.prrv.2023.09.001_b0345","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.jcf.2017.11.016","article-title":"Effect of Lumacaftor\/Ivacaftor on glucose metabolism and insulin secretion in Phe508del homozygous cystic fibrosis patients","volume":"17","author":"Thomassen","year":"2018","journal-title":"J Cyst Fibros"},{"issue":"2","key":"10.1016\/j.prrv.2023.09.001_b0350","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.jcf.2021.09.001","article-title":"The effect of elexacaftor\/tezacaftor\/ivacaftor (ETI) on glycemia in adults with cystic fibrosis","volume":"21","author":"Scully","year":"2022","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.prrv.2023.09.001_b0355","article-title":"Glycemia and \u03b2-cell function before and after elexacaftor\/tezacaftor\/ivacaftor in youth and adults with cystic fibrosis","volume":"30","author":"Chan","year":"2022","journal-title":"J Clin Transl Endocrinol"},{"issue":"14","key":"10.1016\/j.prrv.2023.09.001_b0360","doi-asserted-by":"crossref","first-page":"4149","DOI":"10.3390\/jcm11144149","article-title":"Impact of CFTR modulators on beta-cell function in children and young adults with cystic fibrosis","volume":"11","author":"Piona","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.prrv.2023.09.001_b0365","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2022.852551","article-title":"Short-term effects of elexacaftor\/tezacaftor\/ivacaftor combination on glucose tolerance in young people with cystic fibrosis\u2014an observational pilot study.","volume":"10","author":"Korten","year":"2022","journal-title":"Front Pediatr"},{"issue":"7006","key":"10.1016\/j.prrv.2023.09.001_b0370","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1136\/bmj.311.7006.655","article-title":"Glucose tolerance in patients with cystic fibrosis: five year prospective study","volume":"311","author":"Lanng","year":"1995","journal-title":"BMJ"},{"issue":"S1","key":"10.1016\/j.prrv.2023.09.001_b0375","doi-asserted-by":"crossref","first-page":"S60","DOI":"10.1002\/ppul.25660","article-title":"Recent advances in the early treatment of cystic fibrosis: bridging the gap to highly effective modulator therapy","volume":"57","author":"Lahiri","year":"2022","journal-title":"Pediatr Pulmonol"},{"issue":"3","key":"10.1016\/j.prrv.2023.09.001_b0380","doi-asserted-by":"crossref","first-page":"e81","DOI":"10.1038\/ctg.2017.10","article-title":"Impact of CFTR modulation on intestinal pH, motility, and clinical outcomes in patients with cystic fibrosis and the G551D mutation","volume":"8","author":"Gelfond","year":"2017","journal-title":"Clin Transl Gastroenterol"},{"issue":"1","key":"10.1016\/j.prrv.2023.09.001_b0385","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-36364-6","article-title":"Impact of CFTR modulation with ivacaftor on gut microbiota and intestinal inflammation","volume":"8","author":"Ooi","year":"2018","journal-title":"Sci Rep"},{"issue":"6","key":"10.1016\/j.prrv.2023.09.001_b0390","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1097\/MPG.0000000000002864","article-title":"Reduced intestinal inflammation with lumacaftor\/ivacaftor in adolescents with cystic fibrosis","volume":"71","author":"T\u00e9tard","year":"2020","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"2","key":"10.1016\/j.prrv.2023.09.001_b0395","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1513\/AnnalsATS.201510-669LE","article-title":"Resolution of intestinal histopathology changes in cystic fibrosis after treatment with ivacaftor","volume":"13","author":"Safe","year":"2016","journal-title":"Ann Am Thorac Soc"},{"issue":"1","key":"10.1016\/j.prrv.2023.09.001_b0400","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jcf.2017.07.001","article-title":"Retrospective observational study of French patients with cystic fibrosis and a Gly551Asp-CFTR mutation after 1 and 2years of treatment with ivacaftor in a real-world setting","volume":"17","author":"Hubert","year":"2018","journal-title":"J Cyst Fibros"},{"issue":"2","key":"10.1016\/j.prrv.2023.09.001_b0405","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jcf.2012.11.010","article-title":"Cirrhosis and other liver disease in cystic fibrosis","volume":"12","author":"Flass","year":"2013","journal-title":"J Cyst Fibros"},{"issue":"6","key":"10.1016\/j.prrv.2023.09.001_b0410","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1097\/MCP.0000000000000428","article-title":"Diagnosis, follow-up and treatment of cystic fibrosis-related liver disease","volume":"23","author":"van de Peppel","year":"2017","journal-title":"Curr Opin Pulm Med"},{"issue":"8","key":"10.1016\/j.prrv.2023.09.001_b0415","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1136\/thoraxjnl-2017-210394","article-title":"Data from the US and UK cystic fibrosis registries support disease modification by CFTR modulation with ivacaftor","volume":"73","author":"Bessonova","year":"2018","journal-title":"Thorax"},{"key":"10.1016\/j.prrv.2023.09.001_b0420","first-page":"A150","article-title":"The effect of modulator therapy on liver function in patients with cystic fibrosis-related liver disease (CFLD)","volume":"104","author":"Dempsey","year":"2019","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.prrv.2023.09.001_b0425","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1176815","article-title":"Real-life impact of highly effective CFTR modulator therapy in children with cystic fibrosis","volume":"14","author":"Olivier","year":"2023","journal-title":"Front Pharmacol"},{"issue":"6","key":"10.1016\/j.prrv.2023.09.001_b0430","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1016\/j.jcf.2016.09.003","article-title":"Bone demineralization is improved by ivacaftor in patients with cystic fibrosis carrying the p.Gly551Asp mutation","volume":"15","author":"Sermet-Gaudelus","year":"2016","journal-title":"J Cyst Fibros"},{"issue":"15","key":"10.1016\/j.prrv.2023.09.001_b0435","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1042\/CS20170995","article-title":"Improvement in exercise duration, lung function and well-being in G551D-cystic fibrosis patients: a double-blind, placebo-controlled, randomized, cross-over study with ivacaftor treatment","volume":"131","author":"Edgeworth","year":"2017","journal-title":"Clin Sci"},{"issue":"1","key":"10.1016\/j.prrv.2023.09.001_b0440","doi-asserted-by":"crossref","DOI":"10.1186\/s12890-019-0866-y","article-title":"Lumacaftor\/ Ivacaftor improves exercise tolerance in patients with Cystic Fibrosis and severe airflow obstruction","volume":"19","author":"Wark","year":"2019","journal-title":"BMC Pulm Med"},{"issue":"3","key":"10.1016\/j.prrv.2023.09.001_b0445","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.jcf.2019.03.001","article-title":"Effects of Lumacaftor\/Ivacaftor on physical activity and exercise tolerance in three adults with cystic fibrosis","volume":"18","author":"Savi","year":"2019","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.prrv.2023.09.001_b0450","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/S1569-1993(23)00190-X","article-title":"WS01.04 Longtime follow-up on exercise capacity and quality of life in people with cystic fibrosis receiving elexacaftor\/tezacaftor\/iIvacaftor & #x2013; a Copenhagen cohort","volume":"22","author":"Philipsen","year":"2023","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.prrv.2023.09.001_b0455","doi-asserted-by":"crossref","DOI":"10.1016\/S1569-1993(23)00430-7","article-title":"P055 No impact of elexacaftor\/tezacaftor\/ivacaftor (ETI) CFTRm therapy on male infertility due to CBAVD in two adult cystic fibrosis patients: case report","volume":"22","author":"Stastna","year":"2023","journal-title":"J Cyst Fibros"},{"issue":"3","key":"10.1016\/j.prrv.2023.09.001_b0460","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.jcf.2020.12.011","article-title":"Elexacafator\/tezacaftor\/ivacaftor resolves subfertility in females with CF: A two center case series","volume":"20","author":"O'Connor","year":"2021","journal-title":"J Cyst Fibros"},{"issue":"3","key":"10.1016\/j.prrv.2023.09.001_b0465","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.clinthera.2023.01.016","article-title":"The impact of highly effective cystic fibrosis transmembrane conductance regulator modulators on the health of female subjects with cystic fibrosis","volume":"45","author":"Taylor-Cousar","year":"2023","journal-title":"Clin Ther"},{"key":"10.1016\/j.prrv.2023.09.001_b0470","first-page":"25","article-title":"Potential impact on fertility of new systemic therapies for cystic fibrosis","volume":"16","author":"Jones","year":"2015","journal-title":"Paediatr Respir Rev"},{"issue":"4","key":"10.1016\/j.prrv.2023.09.001_b0475","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.jcf.2017.05.008","article-title":"Worsening anxiety and depression after initiation of lumacaftor\/ivacaftor combination therapy in adolescent females with cystic fibrosis","volume":"16","author":"McKinzie","year":"2017","journal-title":"J Cyst Fibros"},{"issue":"3","key":"10.1016\/j.prrv.2023.09.001_b0480","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.jcf.2021.01.007","article-title":"Challenges in the use of highly effective modulator treatment for cystic fibrosis","volume":"20","author":"Ramos","year":"2021","journal-title":"J Cyst Fibros"},{"issue":"3","key":"10.1016\/j.prrv.2023.09.001_b0485","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.jcf.2021.03.006","article-title":"Maternal and fetal outcomes following elexacaftor-tezacaftor-ivacaftor use during pregnancy and lactation","volume":"20","author":"Taylor-Cousar","year":"2021","journal-title":"J Cyst Fibros"},{"issue":"2","key":"10.1016\/j.prrv.2023.09.001_b0490","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01208-2019","article-title":"ERS\/TSANZ Task Force Statement on the management of reproduction and pregnancy in women with airways diseases","volume":"55","author":"Middleton","year":"2020","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.prrv.2023.09.001_b0495","article-title":"Prospectively evaluating maternal and fetal outcomes in the era of CFTR modulators: the MAYFLOWERS observational clinical trial study design.","volume":"9","author":"Jain","year":"2022","journal-title":"BMJ Open Respir Res"},{"issue":"5","key":"10.1016\/j.prrv.2023.09.001_b0500","doi-asserted-by":"crossref","first-page":"e39","DOI":"10.1016\/j.jcf.2020.04.017","article-title":"Testicular pain following initiation of elexacaftor\/tezacaftor\/ivacaftor in males with cystic fibrosis","volume":"19","author":"Rotolo","year":"2020","journal-title":"J Cyst Fibros"},{"issue":"2","key":"10.1016\/j.prrv.2023.09.001_b0505","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.jcf.2021.10.002","article-title":"Mental status changes during elexacaftor\/tezacaftor \/ ivacaftor therapy","volume":"21","author":"Heo","year":"2022","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.prrv.2023.09.001_b0510","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1156621","article-title":"Individualized approach to elexacaftor\/tezacaftor\/ivacaftor dosing in cystic fibrosis, in response to self-reported anxiety and neurocognitive adverse events: A case series","volume":"14","author":"Ibrahim","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.prrv.2023.09.001_b0515","doi-asserted-by":"crossref","unstructured":"Zhang, L., et al., Impact of elexacaftor\/tezacaftor\/ivacaftor on depression and anxiety in cystic fibrosis. Therapeutic Advances in Respiratory Disease, 2022. 16: p. 17534666221144211.","DOI":"10.1177\/17534666221144211"},{"issue":"7","key":"10.1016\/j.prrv.2023.09.001_b0520","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1002\/ppul.26412","article-title":"Management of neuropsychiatric symptoms in adults treated with elexacaftor\/tezacaftor\/ivacaftor","volume":"58","author":"Baroud","year":"2023","journal-title":"Pediatr Pulmonol"},{"issue":"4","key":"10.1016\/j.prrv.2023.09.001_b0525","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.psym.2017.04.001","article-title":"Cystic fibrosis transmembrane regulator modulators: implications for the management of depression and anxiety in cystic fibrosis","volume":"58","author":"Talwalkar","year":"2017","journal-title":"Psychosomatics"},{"issue":"6","key":"10.1016\/j.prrv.2023.09.001_b0530","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.psym.2020.06.021","article-title":"Trikafta and psychopathology in cystic fibrosis: A case report","volume":"61","author":"Tindell","year":"2020","journal-title":"Psychosomatics"},{"issue":"9","key":"10.1016\/j.prrv.2023.09.001_b0535","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1056\/NEJMoa2100665","article-title":"Triple therapy for cystic fibrosis phe508del\u2013gating and \u2013residual function genotypes","volume":"385","author":"Barry","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.prrv.2023.09.001_b0540","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1179208","article-title":"Effects of elexacaftor\/tezacaftor\/ivacaftor therapy on mental health of patients with cystic fibrosis","volume":"14","author":"Piehler","year":"2023","journal-title":"Front Pharmacol"},{"issue":"2","key":"10.1016\/j.prrv.2023.09.001_b0545","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S2213-2600(16)30427-1","article-title":"Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study","volume":"5","author":"Konstan","year":"2017","journal-title":"Lancet Respir Med"},{"issue":"5","key":"10.1016\/j.prrv.2023.09.001_b0550","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.jcf.2022.04.010","article-title":"Onset of systemic arterial hypertension after initiation of elexacaftor\/tezacaftor\/ivacaftor in adults with cystic fibrosis: A case series","volume":"21","author":"Gramegna","year":"2022","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.prrv.2023.09.001_b0555","doi-asserted-by":"crossref","unstructured":"Diseroad, E.R., P.J. Mogayzel, Jr., and A. Pan, Rechallenge of Elexacaftor\/Tezacaftor\/Ivacaftor After Skin Rash in Two Pediatric Patients. J Pediatr Pharmacol Ther, 2022. 27(5): p. 463-466.","DOI":"10.5863\/1551-6776-27.5.463"},{"issue":"12","key":"10.1016\/j.prrv.2023.09.001_b0560","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0209026","article-title":"Corticosteroid use and increased CXCR2 levels on leukocytes are associated with lumacaftor\/ivacaftor discontinuation in cystic fibrosis patients homozygous for the F508del CFTR mutation","volume":"13","author":"Pohl","year":"2018","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.prrv.2023.09.001_b0565","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.jaci.2020.05.041","article-title":"Drug allergy to CFTR modulator therapy associated with lumacaftor-specific CD4<sup>+<\/sup> T lymphocytes","volume":"147","author":"Roehmel","year":"2021","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.prrv.2023.09.001_b0570","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1111\/cod.14002","article-title":"Toxic epidermal necrolysis induced by cystic fibrosis transmembrane conductance regulator modulators","volume":"86","author":"Mederos\u2010Luis","year":"2022","journal-title":"Contact Dermatitis"},{"issue":"4","key":"10.1016\/j.prrv.2023.09.001_b0575","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.jcf.2019.09.009","article-title":"Longitudinal changes in lung function following initiation of lumacaftor\/ivacaftor combination","volume":"19","author":"Loukou","year":"2020","journal-title":"J Cyst Fibros"},{"issue":"1","key":"10.1016\/j.prrv.2023.09.001_b0580","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1136\/archdischild-2015-310420","article-title":"The impact of 12 months treatment with ivacaftor on Scottish paediatric patients with cystic fibrosis with the G551D mutation: a review","volume":"103","author":"Dryden","year":"2018","journal-title":"Arch Dis Child"},{"issue":"S44","key":"10.1016\/j.prrv.2023.09.001_b0585","doi-asserted-by":"crossref","first-page":"S61","DOI":"10.1002\/ppul.23505","article-title":"Therapeutic challenges posed by critical drug\u2013drug interactions in cystic fibrosis","volume":"51","author":"Jordan","year":"2016","journal-title":"Pediatr Pulmonol"},{"issue":"3","key":"10.1016\/j.prrv.2023.09.001_b0590","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/cts.12610","article-title":"Pharmacokinetic and drug-drug interaction profiles of the combination of tezacaftor\/ivacaftor","volume":"12","author":"Garg","year":"2019","journal-title":"Clin Transl Sci"},{"issue":"2","key":"10.1016\/j.prrv.2023.09.001_b0595","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1002\/ppul.26241","article-title":"Clearing up the smoke: Physical and mental health considerations regarding cannabis use in adolescents with cystic fibrosis","volume":"58","author":"Ince","year":"2023","journal-title":"Pediatr Pulmonol"},{"issue":"6","key":"10.1016\/j.prrv.2023.09.001_b0600","doi-asserted-by":"crossref","first-page":"589","DOI":"10.3390\/genes11060589","article-title":"The changing epidemiology of cystic fibrosis: incidence, survival and impact of the CFTR gene discovery","volume":"11","author":"Scotet","year":"2020","journal-title":"Genes (Basel)"},{"issue":"Suppl 1","key":"10.1016\/j.prrv.2023.09.001_b0605","first-page":"S5","article-title":"Increasing life expectancy in cystic fibrosis: advances and challenges","volume":"57","author":"McBennett","year":"2022","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.prrv.2023.09.001_b0610","first-page":"3","article-title":"CFTR modulator therapies \u2013 Effect on life expectancy in people with cystic fibrosis","volume":"42","author":"Balfour-Lynn","year":"2022","journal-title":"Paediatr Respir Rev"},{"issue":"4","key":"10.1016\/j.prrv.2023.09.001_b0615","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jcf.2023.02.004","article-title":"Elexacaftor\/tezacaftor\/ivacaftor projected survival and long-term health outcomes in people with cystic fibrosis homozygous for F508del","volume":"22","author":"Lopez","year":"2023","journal-title":"J Cyst Fibros"},{"issue":"6","key":"10.1016\/j.prrv.2023.09.001_b0620","doi-asserted-by":"crossref","first-page":"e87","DOI":"10.1016\/j.lpm.2017.04.012","article-title":"The changing epidemiology and demography of cystic fibrosis","volume":"46","author":"Stephenson","year":"2017","journal-title":"Presse Med"},{"issue":"3","key":"10.1016\/j.prrv.2023.09.001_b0625","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.jcf.2022.12.009","article-title":"Effect of elexacaftor\/tezacaftor\/ivacaftor on annual rate of lung function decline in people with cystic fibrosis","volume":"22","author":"Lee","year":"2023","journal-title":"J Cyst Fibros"},{"issue":"6","key":"10.1016\/j.prrv.2023.09.001_b0630","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1183\/13993003.01444-2015","article-title":"Forecasting US ivacaftor outcomes and cost in cystic fibrosis patients with the G551D mutation","volume":"47","author":"Dilokthornsakul","year":"2016","journal-title":"Eur Respir J"},{"issue":"10","key":"10.1016\/j.prrv.2023.09.001_b0635","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/j.jval.2017.06.014","article-title":"Forecasting the long-term clinical and economic outcomes of lumacaftor\/ivacaftor in cystic fibrosis patients with homozygous phe508del mutation","volume":"20","author":"Dilokthornsakul","year":"2017","journal-title":"Value Health"},{"issue":"1","key":"10.1016\/j.prrv.2023.09.001_b0640","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s41030-020-00115-8","article-title":"Real-world outcomes among patients with cystic fibrosis treated with ivacaftor: 2012\u20132016 experience","volume":"6","author":"Higgins","year":"2020","journal-title":"Pulmonary Therapy"},{"issue":"2","key":"10.1016\/j.prrv.2023.09.001_b0645","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jcf.2021.02.003","article-title":"PROMISE: working with the CF community to understand emerging clinical and research needs for those treated with highly effective CFTR modulator therapy","volume":"20","author":"Nichols","year":"2021","journal-title":"J Cyst Fibros"},{"issue":"1","key":"10.1016\/j.prrv.2023.09.001_b0650","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/s41467-023-36244-2","article-title":"Future therapies for cystic fibrosis","volume":"14","author":"Allen","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.prrv.2023.09.001_b0655","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(23)01609-4","article-title":"CFTR modulator therapy: transforming the landscape of clinical care in cystic fibrosis","author":"Taylor-Cousar","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.prrv.2023.09.001_b0660","unstructured":"ISRCTN14081521. A randomised open-label trial to assess change in respiratory function for people with cystic fibrosis (pwCF) established on triple combination therapy (Kaftrio\u2122) after rationalisation of nebulised mucoactive therapies (the CF STORM trial). 2021; Available from: https:\/\/www.isrctn.com\/ISRCTN14081521."}],"container-title":["Paediatric Respiratory Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526054223000647?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526054223000647?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T19:36:55Z","timestamp":1761507415000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526054223000647"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":132,"alternative-id":["S1526054223000647"],"URL":"https:\/\/doi.org\/10.1016\/j.prrv.2023.09.001","relation":{},"ISSN":["1526-0542"],"issn-type":[{"value":"1526-0542","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Trials and tribulations of highly effective modulator therapies in cystic fibrosis","name":"articletitle","label":"Article Title"},{"value":"Paediatric Respiratory Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prrv.2023.09.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2023 Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}